ZA200201923B - Viral replicons and viruses dependent on inducing agents. - Google Patents
Viral replicons and viruses dependent on inducing agents. Download PDFInfo
- Publication number
- ZA200201923B ZA200201923B ZA200201923A ZA200201923A ZA200201923B ZA 200201923 B ZA200201923 B ZA 200201923B ZA 200201923 A ZA200201923 A ZA 200201923A ZA 200201923 A ZA200201923 A ZA 200201923A ZA 200201923 B ZA200201923 B ZA 200201923B
- Authority
- ZA
- South Africa
- Prior art keywords
- replicon
- virus
- replication
- hiv
- rtta
- Prior art date
Links
- 230000001939 inductive effect Effects 0.000 title claims abstract description 55
- 230000003612 virological effect Effects 0.000 title claims abstract description 34
- 241000700605 Viruses Species 0.000 title claims description 117
- 230000001419 dependent effect Effects 0.000 title claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 38
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 27
- 230000002238 attenuated effect Effects 0.000 claims abstract description 23
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 9
- 102000003945 NF-kappa B Human genes 0.000 claims abstract description 9
- 230000010076 replication Effects 0.000 claims description 68
- 101150024821 tetO gene Proteins 0.000 claims description 38
- 229960005486 vaccine Drugs 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 29
- 230000029812 viral genome replication Effects 0.000 claims description 23
- 101710149951 Protein Tat Proteins 0.000 claims description 22
- 239000012190 activator Substances 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 108700004028 nef Genes Proteins 0.000 claims description 10
- 101150023385 nef gene Proteins 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 208000030507 AIDS Diseases 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 2
- JBIWCJUYHHGXTC-AKNGSSGZSA-N doxycycline Chemical compound O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O JBIWCJUYHHGXTC-AKNGSSGZSA-N 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 43
- 230000014509 gene expression Effects 0.000 abstract description 31
- 230000001105 regulatory effect Effects 0.000 abstract description 15
- 230000001976 improved effect Effects 0.000 abstract description 8
- 230000002068 genetic effect Effects 0.000 abstract description 6
- 108700004027 tat Genes Proteins 0.000 abstract description 5
- 101150098170 tat gene Proteins 0.000 abstract description 5
- 229940124590 live attenuated vaccine Drugs 0.000 abstract description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 abstract description 3
- 229940033332 HIV-1 vaccine Drugs 0.000 abstract description 2
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 42
- 208000031886 HIV Infections Diseases 0.000 description 39
- 238000012217 deletion Methods 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 230000037430 deletion Effects 0.000 description 17
- 241000713311 Simian immunodeficiency virus Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 108700039887 Essential Genes Proteins 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000003362 replicative effect Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 230000001042 autoregulative effect Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- 230000002103 transcriptional effect Effects 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 229960003722 doxycycline Drugs 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000035892 strand transfer Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 241000282553 Macaca Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 229940124718 AIDS vaccine Drugs 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101710149136 Protein Vpr Proteins 0.000 description 2
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000014493 regulation of gene expression Effects 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 229960001852 saquinavir Drugs 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000002435 Cyclin T Human genes 0.000 description 1
- 108010068106 Cyclin T Proteins 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010074124 Escherichia coli Proteins Proteins 0.000 description 1
- 241001197893 Glyptemys herpesvirus Species 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 102220470387 Thymosin beta-10_Y26A_mutation Human genes 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102220002645 rs104894309 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99202971A EP1083230A1 (fr) | 1999-09-10 | 1999-09-10 | Replicon viral et virus dépendant d'agents inducteurs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200201923B true ZA200201923B (en) | 2003-09-23 |
Family
ID=8240635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200201923A ZA200201923B (en) | 1999-09-10 | 2002-03-07 | Viral replicons and viruses dependent on inducing agents. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20030099613A1 (fr) |
| EP (2) | EP1083230A1 (fr) |
| JP (1) | JP2003509059A (fr) |
| AT (1) | ATE428792T1 (fr) |
| AU (1) | AU780984B2 (fr) |
| CA (1) | CA2386530A1 (fr) |
| DE (1) | DE60042026D1 (fr) |
| WO (1) | WO2001020013A2 (fr) |
| ZA (1) | ZA200201923B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1479774A1 (fr) * | 2003-05-20 | 2004-11-24 | Academisch Medisch Centrum | Virus dependants d'agents inducteurs pour la penetration cellulaire |
| EP1627563A1 (fr) | 2004-08-10 | 2006-02-22 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Moyens et méthodes de préparation de cellules stabilisées |
| CA2630348C (fr) * | 2005-11-17 | 2016-01-12 | Stichting Voor De Technische Wetenschappen | Systemes d'expression inductible |
| USRE49583E1 (en) | 2005-11-17 | 2023-07-18 | Tet Systems Gmbh & Co. Kg | Inducible expression systems |
| ES2660899T3 (es) | 2005-12-09 | 2018-03-26 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Medios y métodos para influir en la estabilidad de las células productoras de anticuerpos |
| US9005974B2 (en) | 2005-12-09 | 2015-04-14 | Academish Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| US9273118B2 (en) | 2009-07-15 | 2016-03-01 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| EP2319918B1 (fr) * | 2009-11-10 | 2013-01-16 | Centre National De La Recherche Scientifique | Vecteur de lentivirus et son utilisation dans l'évolution dirigée des régions génomiques, gènes et polynucléotides |
| CN103429615B (zh) | 2010-12-02 | 2018-03-16 | 埃姆医疗有限公司 | 用于生产高亲和力抗体的方式和方法 |
| AU2015211480B2 (en) | 2014-01-31 | 2020-05-14 | Kling Biotherapeutics B.V. | Means and methods for producing stable antibodies |
| CN111521359A (zh) * | 2020-04-29 | 2020-08-11 | 河南工程学院 | 面向结构振动主动控制优化配置方法及振动控制实验平台 |
| CN118360259B (zh) * | 2024-06-18 | 2024-09-27 | 苏州药明检测检验有限责任公司 | 一种条件复制型hiv弱毒株及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4100594A1 (de) * | 1991-01-08 | 1992-07-09 | Inst Genbiologische Forschung | Neue plasmide zur zeitlichen und oertlichen kontrollierten expression eines heterologen produktes in pflanzen |
| DK0584348T3 (da) * | 1992-03-11 | 2005-09-19 | Powderject Vaccines Inc | Genetisk vaccine mod immundefektvirusser |
| US5723765A (en) * | 1994-08-01 | 1998-03-03 | Delta And Pine Land Co. | Control of plant gene expression |
| FR2735789B1 (fr) * | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
| US5965440A (en) * | 1995-12-07 | 1999-10-12 | The General Hospital Corporation | Controlled gene product delivery from a regulatable retroviral vector |
| WO1997048277A1 (fr) * | 1996-06-20 | 1997-12-24 | The Salk Institute For Biological Studies | Vecteurs retroviraux a structure modulaire et leurs utilisations |
| GB9621680D0 (en) * | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
| WO1998037185A2 (fr) * | 1997-02-20 | 1998-08-27 | The Board Of Regents Of The University Of Texas System | Vecteurs pour expression genique regulee |
| US5972650A (en) * | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
| US6121021A (en) * | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
| ATE476513T1 (de) * | 1998-12-22 | 2010-08-15 | Dow Agrosciences Llc | Verfahren zum limitieren des herauskreuzens und unerwünschten genflusses in nutzpflanzen |
| ATE292186T1 (de) * | 1999-07-28 | 2005-04-15 | Stephen Smith | Konditionell kontrollierter, attenuierter hiv-1 impfstoff |
-
1999
- 1999-09-10 EP EP99202971A patent/EP1083230A1/fr not_active Withdrawn
-
2000
- 2000-09-08 WO PCT/NL2000/000637 patent/WO2001020013A2/fr active IP Right Grant
- 2000-09-08 AT AT00963145T patent/ATE428792T1/de not_active IP Right Cessation
- 2000-09-08 EP EP00963145A patent/EP1212446B1/fr not_active Expired - Lifetime
- 2000-09-08 DE DE60042026T patent/DE60042026D1/de not_active Expired - Fee Related
- 2000-09-08 AU AU74595/00A patent/AU780984B2/en not_active Ceased
- 2000-09-08 JP JP2001523784A patent/JP2003509059A/ja active Pending
- 2000-09-08 CA CA002386530A patent/CA2386530A1/fr not_active Abandoned
-
2002
- 2002-03-07 ZA ZA200201923A patent/ZA200201923B/en unknown
- 2002-03-08 US US10/097,542 patent/US20030099613A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1083230A1 (fr) | 2001-03-14 |
| EP1212446A2 (fr) | 2002-06-12 |
| DE60042026D1 (de) | 2009-05-28 |
| WO2001020013A3 (fr) | 2001-09-27 |
| CA2386530A1 (fr) | 2001-03-22 |
| AU780984B2 (en) | 2005-04-28 |
| EP1212446B1 (fr) | 2009-04-15 |
| AU7459500A (en) | 2001-04-17 |
| JP2003509059A (ja) | 2003-03-11 |
| ATE428792T1 (de) | 2009-05-15 |
| US20030099613A1 (en) | 2003-05-29 |
| WO2001020013A2 (fr) | 2001-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Verhoef et al. | Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat | |
| Desrosiers | HIV with multiple gene deletions as a live attenuated vaccine for AIDS | |
| Shibata et al. | Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus | |
| EP1954811B1 (fr) | Systeme d'expression inductible | |
| AU780984B2 (en) | Viral replicons and viruses dependent on inducing agents | |
| US6541003B1 (en) | Conditionally controlled, attenuated HIV vaccine | |
| Das et al. | A conditionally replicating virus as a novel approach toward an HIV vaccine | |
| CA2330618C (fr) | Chimeres virales comprenant des elements genetiques de caev et de vih-1 | |
| US20080234215A1 (en) | DNA composition and uses thereof | |
| USRE49583E1 (en) | Inducible expression systems | |
| Smith et al. | Constitutively dead, conditionally live HIV-1 genomes | |
| US20030232060A1 (en) | Attenuated, doxycycline-inducible human immunodeficiency virus proviral molecular clones | |
| Centlivre et al. | A conditionally replicating human immunodeficiency virus in BRG-HIS mice | |
| US6063374A (en) | Recombinant HIV and modified packaging cells and method for using | |
| Deschamps et al. | Genetic construction and in vitro characterization of SIVsmmPBj14-1.9 noninfectious particles | |
| Christie | Immune Evasion and Viral Replication: Examining the Pressures that Influence the Evolution of CD8+ T-cell Epitope Sequences During HIV Infection | |
| Legrand et al. | A doxycycline-dependent HIV-1 replicates in vivo without inducing CD4+ T cell depletion | |
| WO2000018430A2 (fr) | Vaccins a virus actif destines a la protection de primates contre des infections et maladies dues au vih-1 | |
| ZA200006314B (en) | Viral chimeras comprised of CAEV and HIV-1 genetic elements. |